Internal Medicine, Rheumatology · Lynn, MA
NPI
1528014289
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
496 Lynnfield St
Lynn, MA, 01904
Phone (781) 593-3400
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.9M
174,923 services
Medicare patients, 2024
1,897
Average age 75
Drug cost, 2024
$5.7M
3,394 prescriptions
Company payments, 2025
$43.25
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Khalid M Syed was code J3262 (injection, tocilizumab, 1 mg), 56,323 times for 16 patients. In total Khalid M Syed billed 174,923 services in 64 codes, and Medicare paid $1.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-08-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 56,323 | 16 | $4.68 | $264K |
| J1756 Injection, iron sucrose, 1 mg | Office | 29,800 | 35 | $0.18 | $5,291 |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 14,594 | 19 | $9.08 | $132K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 12,625 | 20 | $33.70 | $425K |
| J0897 Injection, denosumab, 1 mg | Office | 12,480 | 135 | $20.28 | $253K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 4,702 | 18 | $24.99 | $118K |
| J9250 Methotrexate sodium, 5 mg | Office | 1,829 | 20 | $0.21 | $387 |
| J9260 Injection, methotrexate sodium, 50 mg | Office | 1,258 | 23 | $2.03 | $2,554 |
| 77080 Standard X-ray | Office | 895 | 892 | $14.25 | $13K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 882 | 177 | $4.61 | $4,069 |
| 96401 Chemotherapy Administration | Office | 844 | 50 | $56.19 | $47K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 802 | 486 | $12.89 | $10K |
| 99214 Office E&M - Established | Office | 703 | 397 | $70.35 | $49K |
| 96413 Chemotherapy Administration | Office | 540 | 86 | $98.69 | $53K |
| 99213 Office E&M - Established | Office | 524 | 368 | $45.91 | $24K |
By year: 2022 $1.5M for 119,640 services; 2023 $1.7M for 170,276 services; 2024 $1.9M for 174,923 services.
Medicare prescription drug claims, 2024
In 2024, the drug Khalid M Syed prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 577 prescriptions and refills. In total Khalid M Syed wrote 3,394 Medicare prescriptions that cost $5.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 577 | 1,467 | 159 | $20K |
| Methotrexate Methotrexate Sodium | 508 | 1,220 | 150 | $15K |
| Prednisone Generic | 360 | 668 | 108 | $2,774 |
| Allopurinol Generic | 349 | 950 | 88 | $3,991 |
| Enbrel Sureclick Etanercept | 215 | 225 | 26 | $1.6M |
| Alendronate Sodium Generic | 124 | 305 | 43 | $1,094 |
| Folic Acid Generic | 101 | 304 | 30 | $1,046 |
| Leucovorin Calcium Generic | 96 | 244 | 28 | $4,094 |
| Enbrel Etanercept | 80 | 100 | 12 | $687K |
| Colchicine Generic | 76 | 110 | 34 | $3,198 |
| Humira(Cf) Pen Adalimumab | 69 | 69 | Under 11 | $544K |
| Celecoxib Generic | 54 | 86 | 15 | $4,848 |
| Sulfasalazine Generic | 50 | 143 | 15 | $2,348 |
| Orencia Clickject Abatacept | 47 | 52 | Under 11 | $289K |
| Cosentyx Sensoready (2 Pens) Secukinumab | 45 | 50 | Under 11 | $354K |
Brand drugs: - claims; generic drugs: 2,459 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Khalid M Syed $43.25 ($43.25 in general payments such as food, travel and fees) from 1 company. The largest payer was AstraZeneca Pharmaceuticals LP with $43.25.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 1 | $43.25 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.